Skip to content
HowShorted

AYTU BIOPHARMA, INC short interest in 2024

In 2024, AYTU BIOPHARMA, INC's disclosed short interest ran from 6.26% of shares outstanding on 12 Jan 2024 to 2.23% on 31 Dec 2024, a change of -4.03 percentage points. The year's high was 8.32% on 31 May 2024 and its low 1.93% on 29 Nov 2024, averaging 5.55% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 58.72 days on 30 Apr 2024. Full history: AYTU BIOPHARMA, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for AYTU BIOPHARMA, INC in 2024

2024 in figures

Start of year
6.26% (12 Jan 2024)
End of year
2.23% (31 Dec 2024)
Change
-4.03 pp
High
8.32% (31 May 2024)
Low
1.93% (29 Nov 2024)
Average
5.55%
Highest days to cover
58.72 (30 Apr 2024)
SEC filings marked
8

Every report in 2024

AYTU BIOPHARMA, INC short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20246.26%33.81
31 Jan 20245.66%24.28
15 Feb 20246.01%13.3410-Q filed, results (8-K)
29 Feb 20246.28%12.20
15 Mar 20246.49%17.23
28 Mar 20246.48%17.24
15 Apr 20247.23%17.74
30 Apr 20246.88%58.72
15 May 20247.53%18.9810-Q filed, results (8-K)
31 May 20248.32%20.78
14 Jun 20248.19%15.97
28 Jun 20247.39%18.69
15 Jul 20247.12%23.36
31 Jul 20246.69%22.22
15 Aug 20245.83%17.14
30 Aug 20245.82%15.61
13 Sep 20245.67%42.13
30 Sep 20244.27%6.4110-K filed, results (8-K)
15 Oct 20243.66%12.06
31 Oct 20243.13%11.00
15 Nov 20241.96%1.9710-Q filed, results (8-K)
29 Nov 20241.93%3.56
13 Dec 20242.06%2.79
31 Dec 20242.23%5.16

See also: AYTU BIOPHARMA, INC's full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.